Marina Biotech and Debiopharm partner on RNAi-based therapies for bladder cancer

4 February 2011

Switzerland-based drug developer Debiopharm and US RNAi-based drug discover Marina Biotech (Nasdaq: MRNA) have entered into an exclusive agreement concerning the development and commercialization of Marina Biotech's preclinical program in bladder cancer.

Under the terms of the deal, Debiopharm will pay Marina Biotech up to $25 million based on predefined R&D milestones as well as royalties on the sales of products resulting from the partnership. In addition, all Marina Biotech R&D costs for the bladder cancer program will be funded by Debiopharm beginning in February 2011. Further terms of the agreement were not disclosed.

Debiopharm and Marina Biotech will work together to advance to market an RNAi-based therapy for the treatment of non-muscle invasive bladder cancer. Debiopharm will have full responsibility for the development and commercialization of any products arising from the partnership.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK